Abstract
We have synthesized a β-cyclodextrin (βCD)-capped histone deacetylase (HDAC) inhibitor 3 containing an alkyl linker and a zinc-binding hydroxamic acid motif. Biological evaluation (HDAC inhibition studies) of 3 enabled us to establish the effect of replacing an aryl cap (in SAHA (vorinostat,)) 1 by a large saccharidic scaffold "cap". HDAC inhibition was observed for 3, to a lesser extent than SAHA, and rationalized by molecular docking into the active site of HDAC8. However, compound 3 displayed no cellular activity.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Binding Sites
-
Cell Line, Tumor
-
Histone Deacetylase Inhibitors / chemistry*
-
Histone Deacetylase Inhibitors / metabolism
-
Histone Deacetylases / chemistry*
-
Histone Deacetylases / metabolism
-
Humans
-
Hydroxamic Acids / chemistry
-
Molecular Docking Simulation
-
Protein Isoforms / antagonists & inhibitors
-
Protein Isoforms / metabolism
-
Protein Structure, Tertiary
-
Repressor Proteins / chemistry*
-
Repressor Proteins / metabolism
-
Vorinostat
-
Zinc / chemistry
-
beta-Cyclodextrins / chemistry*
-
beta-Cyclodextrins / metabolism
Substances
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Protein Isoforms
-
Repressor Proteins
-
beta-Cyclodextrins
-
Vorinostat
-
HDAC8 protein, human
-
Histone Deacetylases
-
Zinc
-
betadex